

AN INVESTIGATION OF LIPOSOMES FOR  
ORAL DELIVERY OF A POORLY BIOAVAILABLE  
MODEL DRUG: GRISEOFULVIN

SANDY ONG GIM MING

UNIVERSITI SAINS MALAYSIA  
2011

**AN INVESTIGATION OF LIPOSOMES FOR ORAL DELIVERY OF A POORLY  
BIOAVAILABLE MODEL DRUG: GRISEOFULVIN**

by

SANDY ONG GIM MING

**Thesis submitted in fulfillment of the requirements  
for the degree of Doctor of Philosophy**

April 2011

To my wonderful parents, Ong Kok Chye and Lee Hoi Gat,  
lovable sisters, Cindy and Wendy,  
and charming little brother, Bernard

## **ACKNOWLEDGMENTS**

First and foremost, I would like to express my sincere appreciation and heartfelt thanks to my supervisor, Prof. Dr. Yuen Kah Hay, for his guidance during my research and study at Universiti Sains Malaysia. His perpetual energy and enthusiasm in research had motivated all his students, including me. In addition, he was always accessible and willing to help his students with their research. As a result, research life became smooth and rewarding for me.

Besides my supervisor, I would like to thank my kind mentors Dr. Wong Jia Woei and Dr. Ng Bee Hong. Their constructive contributions, invaluable advices and critical comments have helped me immensely in every way. My sincere appreciations also go to Samer and Mei Mei for being my valuable source of ideas and motivation as well. I am also grateful to Enrico Magosso for helping me with the surgical procedures for lymphatic cannulation. Moreover, I would like to express my gratitude to Ai Beoy, Erena and Hwee Ching for their help in the animal studies. Also, I am indebted to Wai Peng and Sin Yee for their assistance with the analytical instruments.

Special thanks to all my friends and colleagues who are equally helpful: Dr. Nurzalina, Dr. Sharon, Dr. Rosa, Dr Anna, Dr Gamal, Dr Jiyauddin, Mr Wan Yoghesh, Siew Siew, Sheau Chin, Belle, Phaik Chin, Kamarul, Kamaliah, Shafiq, Kok Seong, Kar Ling, Pay Kim, Mei Ching, Hooi Yin, June, Song

Thai, Li Ying, Sabiha, Mahmoud, Yanti, Gan, Ying Yu, Luen Hui, Chiu Yin, Wai Yee and Vijay.

I would like to thank Hovid Bhd. for providing a very conducive atmosphere for research as well as their generous support for the study. My appreciation also goes to the Dean and staff of the School of Pharmaceutical Sciences, USM, especially En. Ibrahim, En. Samsuddin, Pn. Salida and En. Azrol, for their support and assistance.

In addition, my deepest gratitude goes to my family members for their continuous encouragement, support and unflagging love. Last but not least, I wish to thank my husband, Kah Seng. His patience and love have sustained me when I thought I could not carry on. Thank you.

# TABLE OF CONTENTS

|  |          |
|--|----------|
| TITLE  | i        |
| DEDICATION   | ii       |
| ACKNOWLEDGEMENTS   | iii      |
| TABLE OF CONTENTS  | v        |
| LIST OF TABLES   | xi       |
| LIST OF FIGURES  | xiv      |
| LIST OF PLATES   | xvi      |
| LIST OF ABBREVIATIONS  | xvii     |
| LIST OF APPENDICES   | xix      |
| ABSTRAK  | xxviii   |
| ABSTRACT   | xxx      |
| <br>   |          |
| <b>CHAPTER 1 INTRODUCTION</b>  | <b>1</b> |
| <br>   |          |
| 1.1 Bioavailability  | 1        |
| 1.1.1 Introduction   | 1        |
| 1.1.2 Definition   | 1        |
| 1.1.3 Barriers affecting oral bioavailability of poorly water-soluble drugs  | 2        |
| 1.1.3(a) Preenterocyte barriers  | 2        |
| 1.1.3(b) Enterocyte barriers   | 5        |
| 1.1.3(c) Postenterocyte barriers   | 6        |
| 1.1.4 Approaches to enhance the oral bioavailability of poorly soluble drugs | 7        |
| 1.1.4(a) Prodrugs  | 7        |
| 1.1.4(b) Complexation  | 8        |
| 1.1.4(c) Cosolvent approach  | 8        |
| 1.1.4(d) Particle size reduction   | 9        |
| 1.1.4(e) Pharmaceutical salts  | 9        |
| 1.1.4(f) Lipid-based formulations  | 10       |

|          |  |    |
|----------|--|----|
| 1.2      | Mechanisms of lipid-based formulations in enhancing the oral bioavailability of poorly water-soluble drugs | 11 |
| 1.2.1    | Digestion and absorption of lipid from gastrointestinal tract  | 13 |
| 1.2.2    | Intestinal lymphatic drug transport  | 15 |
| 1.3      | Liposomes  | 17 |
| 1.3.1    | Introduction   | 17 |
| 1.3.2    | Classification of liposomes  | 20 |
| 1.3.3    | Chemical constituents  | 22 |
| 1.3.4    | Methods of preparation   | 24 |
| 1.3.4(a) | Mechanical dispersion  | 26 |
| 1.3.4(b) | Solvent dispersion   | 29 |
| 1.3.4(c) | Detergent solubilisation   | 32 |
| 1.3.5    | Characterisation of liposomes  | 32 |
| 1.3.5(a) | Size   | 32 |
| 1.3.5(b) | Number of lamellae   | 34 |
| 1.3.5(c) | Encapsulation volume   | 34 |
| 1.3.5(d) | Encapsulation efficiency   | 35 |
| 1.3.5(e) | Bilayer fluidity   | 35 |
| 1.3.5(f) | Charge   | 35 |
| 1.3.6    | Advantages of liposomal drug formulations  | 36 |
| 1.3.7    | Limitations of liposomal drug formulations   | 37 |
| 1.4      | Griseofulvin as model drug   | 38 |
| 1.4.1    | Introduction   | 38 |
| 1.4.2    | Description  | 39 |
| 1.4.3    | Mechanism of action  | 40 |
| 1.4.4    | Pharmacokinetic properties   | 41 |
| 1.4.5    | Griseofulvin formulations with enhanced bioavailability  | 41 |
| 1.5      | Summary and scope of study   | 42 |

|   |           |
|---|-----------|
| <b>CHAPTER 2 EVALUATION OF EXTRUSION TECHNIQUE FOR<br/>NANOSIZING LIPOSOMES</b> | <b>44</b> |
|---|-----------|

|   |    |
|---|----|
| 2.1 Introduction                                      | 44 |
| 2.2 Materials   | 48 |
| 2.3 Instrumentation                                   | 48 |
| 2.4 Methods   | 49 |
| 2.4.1 Preparation of blank liposome                   | 49 |
| 2.4.2 Extrusion procedure                             | 49 |
| 2.5 Assessment of liposome size and size distribution | 51 |
| 2.6 Results   | 52 |
| 2.6.1 Influence of process parameters                 | 52 |
| 2.6.2 Comparison with other size reducing methods     | 59 |
| 2.7 Discussion  | 61 |
| 2.8 Conclusion  | 68 |

|  |           |
|--|-----------|
| <b>CHAPTER 3 FORMULATION DEVELOPMENT</b> | <b>70</b> |
|--|-----------|

|   |    |
|---|----|
| 3.1 Introduction  | 70 |
| 3.2 Materials   | 71 |
| 3.3 Methods   | 73 |
| 3.3.1 Preparation of blank liposomes and griseofulvin-loaded liposomes                | 73 |
| 3.3.2 Particle size analysis  | 75 |
| 3.3.3 Zeta potential analysis   | 75 |
| 3.3.4 Determination of encapsulation efficiency                                       | 76 |
| 3.3.4(a) Separation of griseofulvin-loaded liposomes from free griseofulvin           | 77 |
| 3.3.4(b) Total griseofulvin   | 78 |
| 3.3.5 Determination of the concentration of free and total griseofulvin concentration | 78 |



|   |         |
|---|---------|
| 3.4 Results   | 79      |
| 3.4.1 Particle size analysis  | 79      |
| 3.4.2 Zeta potential analysis   | 94      |
| 3.4.3 Determination of encapsulation efficiency   | 102     |
| 3.5 Discussion  | 110     |
| 3.6 Conclusion  | 116     |
| <br><b>CHAPTER 4. INFLUENCE OF THE ENCAPSULATION EFFICIENCY<br/>ON THE BIOAVAILABILITY OF THE LIPOSOMAL<br/>FORMULATION</b> | <br>118 |
| 4.1 Introduction  | 118     |
| 4.2 Materials   | 119     |
| 4.3 Methods   | 119     |
| 4.3.1 Methods of preparation of drug aqueous suspension<br>and liposomal formulations                                       | 119     |
| 4.3.2 Assessment of particle size and encapsulation<br>efficiency   | 121     |
| 4.3.3 <i>In vivo</i> study protocol   | 121     |
| 4.3.4 Analysis of plasma griseofulvin concentration   | 122     |
| 4.3.5 Data and pharmacokinetic analysis   | 124     |
| 4.3.6 Statistical analysis  | 124     |
| 4.4 Results   | 125     |
| 4.4.1 Particle size and encapsulation efficiency  | 125     |
| 4.4.2 <i>In vivo</i> comparative bioavailability study  | 128     |
| 4.5 Discussion  | 131     |
| 4.6 Conclusion  | 133     |

**CHAPTER 5 THE EFFECT OF LIPOSOMAL FORMULATION ON LYMPHATIC TRANSPORT OF ENCAPSULATED DRUG AFTER ABSORPTION** 134

|       |  |     |
|-------|--|-----|
| 5.1   | Introduction   | 134 |
| 5.2   | Materials  | 134 |
| 5.2.1 | Chemicals  | 134 |
| 5.2.2 | Surgical equipments  | 135 |
| 5.3   | Methods  | 135 |
| 5.3.1 | Preparation of drug aqueous suspension and drug-loaded liposomes | 135 |
| 5.3.2 | Experimental procedures  | 136 |
| 5.3.3 | Cannulation of intestinal mesenteric lymph                       | 137 |
| 5.3.4 | Analysis of griseofulvin in plasma and lymph                     | 139 |
| 5.3.5 | Data analysis  | 140 |
| 5.3.6 | Statistical analysis   | 140 |
| 5.4   | Results  | 141 |
| 5.5   | Discussion   | 143 |
| 5.6   | Conclusion   | 146 |

**CHAPTER 6 INFLUENCE OF THE LIPOSOMAL PARTICLE SIZE ON THE BIOAVAILABILITY OF THE LIPOSOMAL FORMULATION** 147

|       |  |     |
|-------|--|-----|
| 6.1   | Introduction   | 147 |
| 6.2   | Materials  | 148 |
| 6.3   | Methods  | 148 |
| 6.3.1 | Method of preparation of liposomal formulations          | 148 |
| 6.3.2 | Assessment of particle size and encapsulation efficiency | 150 |
| 6.3.3 | <i>In vivo</i> study protocol                            | 150 |
| 6.3.4 | Analysis of plasma griseofulvin concentration            | 152 |
| 6.3.5 | Data and pharmacokinetic analysis                        | 152 |

|   |  |     |
|---|--|-----|
| 6.3.6   | Statistical analysis                             | 153 |
| 6.4   | Results  | 154 |
| 6.4.1   | Particle size and encapsulation efficiency       | 154 |
| 6.4.2   | <i>In vivo</i> comparative bioavailability study | 157 |
| 6.5   | Discussion                                       | 161 |
| 6.6   | Conclusion                                       | 163 |
| <b>CHAPTER 7 SUMMARY AND GENERAL CONCLUSION</b> |  | 164 |
| <b>CHAPTER 8 SUGGESTIONS FOR FURTHER WORK</b>   |  | 167 |
| <b>REFERENCES</b>                               |  | 169 |
| <b>APPENDICES</b>                               |  | 192 |

## ***LIST OF TABLES***

|        |  |    |
|--------|--|----|
| 1.1    | List of parameters and common techniques for characterizing liposomes  | 33 |
| 2.1    | Particle size of liposomes after treatment with various size reduction methods (Mean $\pm$ SEM, n=6)   | 60 |
| 3.1    | The contents of various pro-liposomes  | 72 |
| 3.2    | Particle size and polydispersity index of blank liposome duo, C and S (Mean $\pm$ SEM, n=18)   | 80 |
| 3.3    | Particle size and polydispersity index of griseofulvin-loaded liposome duo, C and S (Mean $\pm$ SEM, n=18)   | 83 |
| 3.4(a) | Effects of duration of mixing and temperature on the particle size of griseofulvin-loaded liposome duo (2mg/g pro-liposomes) (Mean $\pm$ SEM, n=12)        | 85 |
| 3.4(b) |  | 85 |
|        | Effects of duration of mixing and temperature on the particle size of griseofulvin-loaded liposome C (2mg/g pro-liposomes) (Mean $\pm$ SEM, n=12)          |    |
| 3.4(c) |  | 86 |
|        | Effects of duration of mixing and temperature on the particle size of griseofulvin-loaded liposome S (2mg/g pro-liposomes) (Mean $\pm$ SEM, n=12)          |    |
| 3.5(a) |  | 88 |
|        | Effects of duration of mixing and temperature on the polydispersity index of griseofulvin-loaded liposome duo (2mg/g pro-liposomes) (Mean $\pm$ SEM, n=12) |    |
| 3.5(b) |  | 88 |
|        | Effects of duration of mixing and temperature on the polydispersity index of griseofulvin-loaded liposome C (2mg/g pro-liposomes) (Mean $\pm$ SEM, n=12)   |    |
| 3.5(c) | Effects of duration of mixing and temperature on the polydispersity index of griseofulvin-loaded liposome S (2mg/g pro-liposomes)                          | 89 |

|         |  |    |
|---------|--|----|
| 3.6(a)  | Effects of different pro-liposomes and solvent on the particle size of various blank liposomes (Mean $\pm$ SEM, n=6)   | 90 |
| 3.6(b)  | Effects of different pro-liposomes and solvent on the polydispersity index of various blank liposomes (Mean $\pm$ SEM, n=6)  | 90 |
| 3.7(a)  | Effects of different pro-liposomes and solvent on the particle size of various griseofulvin-loaded liposomes (2mg/g pro-liposomes) (Mean $\pm$ SEM, n=6)           | 92 |
| 3.7(b)  | Effects of different pro-liposomes and solvent on the polydispersity index of various griseofulvin-loaded liposome duo (2mg/g pro-liposomes) (Mean $\pm$ SEM, n=6) | 92 |
| 3.8     | Effects of drug amount added on the particle size and polydispersity index of griseofulvin-loaded liposomes duo (Mean $\pm$ SEM, n=3)                              | 93 |
| 3.9     | Zeta potential of blank liposome duo, C and S (Mean $\pm$ SEM, n=3)  | 95 |
| 3.10    | Zeta potential of griseofulvin-loaded liposome duo, C and S (Mean $\pm$ SEM, n=3)  | 95 |
| 3.11(a) | Effects of mixing duration and temperature on the zeta potential of griseofulvin-loaded liposome duo (2mg/g pro-liposomes) (Mean $\pm$ SEM, n=3)                   | 96 |
| 3.11(b) | Effects of mixing duration and temperature on the zeta potential of griseofulvin-loaded liposome C (2mg/g pro-liposomes) (Mean $\pm$ SEM, n=3)                     | 96 |
| 3.11(c) | Effects of mixing duration and temperature on the zeta potential of griseofulvin-loaded liposome C (2mg/g pro-liposomes) (Mean $\pm$ SEM, n=3)                     | 97 |
| 3.12    | Zeta potential of blank liposomes prepared using different pro-liposomes and solvent (Mean $\pm$ SEM, n=3)   | 99 |

|      |   |     |
|------|---|-----|
| 3.13 | Effects of different pro-liposomes and solvent on the zeta potential of griseofulvin-loaded liposomes (2mg/g pro-liposomes) (Mean $\pm$ SEM, n=3)   | 99  |
| 3.14 | Effects of different amount of griseofulvin added on the zeta potential values of griseofulvin-loaded liposomes duo prepared using chloroform as solvent (Mean $\pm$ SEM, n=3)  | 101 |
| 3.15 | The encapsulation efficiency of various griseofulvin-loaded liposomes (2mg/g pro-liposomes) (Mean $\pm$ SEM, n=3)   | 105 |
| 3.16 | The effects of different pro-liposomes and solvents on encapsulation efficiency of griseofulvin-loaded liposomes (2mg/g pro-liposome) (Mean $\pm$ SEM, n=3)   | 109 |
| 3.17 | Effects of amount of griseofulvin added on the encapsulation efficiency of griseofulvin-loaded liposomes duo (Mean $\pm$ SEM, n=3)  | 109 |
| 4.1  | Sequence of administration of griseofulvin aqueous suspension, liposomal formulation 1 and liposomal formulation 2  | 123 |
| 4.2  | Particle size and size distribution of liposomal formulation 1 and liposomal formulation 2 prepared using different forms of griseofulvin (Mean $\pm$ SEM, n=18)  | 126 |
| 4.3  | Percentage of griseofulvin encapsulated in liposomal formulation 1 and liposomal formulation 2 prepared using different forms of griseofulvin (Mean $\pm$ SEM, n=6)   | 127 |
| 4.4  | Individual values of $C_{max}$ , $T_{max}$ , $AUC_{0-t}$ and 90% confidence interval for griseofulvin after oral administration of griseofulvin aqueous suspension, liposomal formulation 1 and liposomal formulation 2 | 130 |
| 6.1  | Sequence of administration of the three types of griseofulvin-loaded liposomes  | 151 |

|     |   |     |
|-----|---|-----|
| 6.2 | Particle size and size distribution of liposomal preparations produced using various mechanical dispersion methods (Mean $\pm$ SEM, n=18)   | 155 |
| 6.3 | Percentage of griseofulvin encapsulated in liposomal preparations produced using various mechanical dispersion methods (Mean $\pm$ SEM, n=6)  | 156 |
| 6.4 | Individual values of $C_{\max}$ , $T_{\max}$ , $AUC_{0-t}$ and 90% confidence interval for griseofulvin after oral administration of griseofulvin-loaded liposomes prepared using various mechanical dispersion methods | 159 |

## ***LIST OF FIGURES***

|     |   |    |
|-----|---|----|
| 1.1 | Barriers affecting oral bioavailability of poorly water-soluble drugs   | 3  |
| 1.2 | Structural formula of a phospholipid molecule   | 18 |
| 1.3 | Distribution of drugs of different lipophilicities in liposomes   | 19 |
| 1.4 | Classification of methods of liposome preparation   | 25 |
| 1.5 | Mechanical dispersion techniques for liposome preparation   | 27 |
| 1.6 | Solvent dispersion techniques for liposome preparation  | 30 |
| 1.7 | Chemical structure of griseofulvin  | 39 |
| 2.1 | Assembly of instrument used for the extrusion process   | 46 |
| 2.2 | Placement of membrane filter in the guard column  | 47 |
| 2.3 | Influence of flow rate on the (a) particle size and (b) polydispersity index of extruded liposomes (Mean $\pm$ SEM, n=6)  | 53 |
| 2.4 | Influence of membrane pore size on the (a) particle size and (b) polydispersity index of extruded liposomes (Mean $\pm$ SEM, n=6)   | 55 |
| 2.5 | Influence of temperature on the (a) particle size and (b) polydispersity index of extruded liposomes (Mean $\pm$ SEM, n=6)  | 58 |
| 2.6 | The physical stability of liposomes prepared using the various size reduction treatments kept at 4°C over 24 weeks (Mean $\pm$ SEM, n=6)  | 62 |
| 3.1 | The stability of particle size for blank liposomes (a) duo, (b) C and (c) S kept under ambient room temperature (25°C), refrigerated conditions (4°C) and frozen conditions (-20°C) (Mean $\pm$ SEM, n=6) | 81 |



|     |   |     |
|-----|---|-----|
| 3.2 | Effect of temperature and duration of mixing on the encapsulation efficiency of griseofulvin-loaded liposome (a) duo, (b) C and (c) S (2mg/g pro-liposomes) (Mean $\pm$ SEM, n=3)                                     | 107 |
| 4.1 | Mean plasma griseofulvin concentration versus time profiles after dosing with griseofulvin aqueous suspension, liposomal formulation 1 and 2 (8mg/kg) (Mean $\pm$ SEM, n=9)   | 129 |
| 5.1 | Ratio of griseofulvin concentration in lymph over that of in plasma versus time profiles of rats (Mean $\pm$ SEM, n=6) after oral administration of griseofulvin aqueous suspension and griseofulvin-loaded liposomes | 142 |
| 6.1 | Mean plasma griseofulvin concentration versus time profiles after dosing with liposomal formulations of various particle size (8mg/kg) (Mean $\pm$ SEM, n=9)  | 158 |

## ***LIST OF PLATES***

- |     |   |     |
|-----|---|-----|
| 3.1 | Micrographs of blank liposomes duo and griseofulvin-loaded liposomes duo (the dark aggregations are griseofulvin particles) | 103 |
| 3.2 | Micrographs of griseofulvin-loaded liposomes before and after centrifugation at 12 800 g for various duration               | 104 |

## ***LIST OF ABBREVIATIONS***

| Abbreviation       | Full name  |
|--------------------|--|
| ANOVA              | Analysis of variance   |
| AUC                | Area under the plasma concentration-time curve   |
| AUC <sub>0-t</sub> | Area under the plasma concentration-time curve from time zero to the last sampling time, t |
| BCS                | Biopharmaceutics Classification System   |
| BS                 | Bile salt  |
| CLs                | Conventional liposomes   |
| C <sub>max</sub>   | Peak plasma concentration  |
| CYP3A4             | Cytochrome P450 subfamily 3A4  |
| DDT                | Dichlorodiphenyltrichloroethane  |
| DG                 | Diglyceride  |
| DSC                | Differential Scanning Calorimetry  |
| EDTA               | Disodium ethylene diamine tetraacetic acid   |
| FA                 | Fatty acid   |
| FDA                | Food and Drug Administration   |
| GI                 | Gastrointestinal   |
| HPLC               | High performance liquid chromatography   |
| ICH                | International Conference on Harmonisation  |
| i.m.               | Intramuscular  |
| i.p.               | Intraperitoneal  |
| i.v.               | Intravenous  |
| LCLs               | Long-circulating liposomes   |
| LUVs               | Large unilamellar vesicles   |
| MDR                | Multiple drug resistance   |
| MFGM               | Milk fat globule membrane  |
| MG                 | 2-monoglyceride  |
| MLVs               | Multilamellar vesicles   |
| MVLs               | Multivesicular liposomes   |

|                  |   |
|------------------|---|
| MVM-FABP         | Microvillus membrane fatty acid binding protein |
| NMR              | Nuclear Magnetic Resonance                      |
| PC               | Phosphatidylcholine                             |
| PCS              | Photon Correlation Spectroscopy                 |
| PE               | Phosphatidylethanolamine                        |
| PEGs             | Polyethylene glycols                            |
| PI               | Phosphatidylinositol                            |
| P-gp             | P-glycoprotein                                  |
| PL               | Phospholipid                                    |
| s.c.             | Subcutaneous                                    |
| SD               | Standard deviation                              |
| SEM              | Standard error mean                             |
| SUVs             | Small unilamellar vesicles                      |
| TG               | Triglyceride                                    |
| TGA              | Thermogravimetry                                |
| T <sub>max</sub> | Time to reach peak plasma concentration         |
| U.S.             | United States                                   |
| UWL              | Unstirred water layer                           |
| v/v              | Volume over volume                              |
| w/w              | Weight over weight                              |
| ZAve             | Z average diameter                              |

## ***LIST OF APPENDICES***

|        |   |     |
|--------|---|-----|
| 2.1(a) | Particle size values of blank liposomes duo after various number of cycles through the extruder at 1mL/min        | 193 |
| 2.1(b) | Particle size values of blank liposomes duo after various number of cycles through the extruder at 5mL/min        | 193 |
| 2.1(c) | Particle size values of blank liposomes duo after various number of cycles through the extruder at 9mL/min        | 193 |
| 2.2(a) | Polydispersity index values of blank liposomes duo after various number of cycles through the extruder at 1mL/min | 194 |
| 2.2(b) | Polydispersity index values of blank liposomes duo after various number of cycles through the extruder at 5mL/min | 194 |
| 2.2(c) | Polydispersity index values of blank liposomes duo after various number of cycles through the extruder at 9mL/min | 194 |
| 2.3(a) | Particle size values of blank liposomes duo after various number of cycles through 2µm membrane filter            | 195 |
| 2.3(b) | Particle size values of blank liposomes duo after various number of cycles through 0.5µm membrane filter          | 196 |
| 2.3(c) | Particle size values of blank liposomes duo after various number of cycles through 0.2µm membrane filter          | 197 |
| 2.3(d) | Particle size values of blank liposomes duo after various number of cycles through 0.1µm membrane filter          | 198 |
| 2.4(a) | Polydispersity index values of blank liposomes duo after various number of cycles through 2µm membrane filter     | 199 |
| 2.4(b) | Polydispersity index values of blank liposomes duo after various number of cycles through 0.5µm membrane filter   | 200 |

|        |  |     |
|--------|--|-----|
| 2.4(c) | Polydispersity index values of blank liposomes duo after various number of cycles through 0.2µm membrane filter          | 201 |
| 2.4(d) | Polydispersity index values of blank liposomes duo after various number of cycles through 0.1µm membrane filter          | 202 |
| 2.5(a) | Particle size values of blank liposomes duo after extrusion through 0.2µm membrane filter at various temperatures        | 203 |
| 2.5(b) | Particle size values of blank liposomes duo after extrusion through 0.1µm membrane filter at various temperatures        | 204 |
| 2.6(a) | Polydispersity index values of blank liposomes duo after extrusion through 0.2µm membrane filter at various temperatures | 205 |
| 2.6(b) | Polydispersity index values of blank liposomes duo after extrusion through 0.1µm membrane filter at various temperatures | 206 |
| 2.7(a) | Particle size values of blank liposomes duo after various size reducing methods at day 0                                 | 207 |
| 2.7(b) | Particle size values of blank liposomes duo after various treatments kept in 4°C for 1 week                              | 207 |
| 2.7(c) | Particle size values of blank liposomes duo after various treatments kept in 4°C for 2 weeks                             | 208 |
| 2.7(d) | Particle size values of blank liposomes duo after various treatments kept in 4°C for 3 weeks                             | 208 |
| 2.7(e) | Particle size values of blank liposomes duo after various treatments kept in 4°C for 4 weeks                             | 209 |
| 2.7(f) | Particle size values of blank liposomes duo after various treatments kept in 4°C for 8 weeks                             | 209 |

|        |   |     |
|--------|---|-----|
| 2.7(g) | Particle size values of blank liposomes duo after various treatments kept in 4°C for 12 weeks | 210 |
| 2.7(h) | Particle size values of blank liposomes duo after various treatments kept in 4°C for 24 weeks | 210 |
| 3.1(a) | Particle size and polydispersity index values of blank liposome duo                           | 211 |
| 3.1(b) | Particle size and polydispersity index values of blank liposome C                             | 212 |
| 3.1(c) | Particle size and polydispersity index values of blank liposome S                             | 213 |
| 3.2(a) | Particle size values of various blank liposomes at day 0                                      | 214 |
| 3.2(b) | Particle size values of various blank liposomes kept in 4°C for 1 week                        | 214 |
| 3.2(c) | Particle size values of various blank liposomes kept in 4°C for 2 weeks                       | 214 |
| 3.2(d) | Particle size values of various blank liposomes kept in 4°C for 3 weeks                       | 214 |
| 3.2(e) | Particle size values of various blank liposomes kept in 4°C for 4 weeks                       | 215 |
| 3.2(f) | Particle size values of various blank liposomes kept in 4°C for 8 weeks                       | 215 |
| 3.2(g) | Particle size values of various blank liposomes kept in 4°C for 12 weeks                      | 215 |
| 3.2(h) | Particle size values of various blank liposomes kept in 4°C for 24 weeks                      | 215 |

|        |   |     |
|--------|---|-----|
| 3.2(i) | Particle size values of various blank liposomes kept in 25°C for 1 week   | 216 |
| 3.2(j) | Particle size values of various blank liposomes kept in 25°C for 2 weeks  | 216 |
| 3.2(k) | Particle size values of various blank liposomes kept in - 20°C for 1 week   | 216 |
| 3.2(l) | Particle size values of various blank liposomes kept in - 20°C for 2 weeks  | 216 |
| 3.2(m) | Particle size values of various blank liposomes kept in - 20°C for 3 weeks  | 217 |
| 3.2(n) | Particle size values of various blank liposomes kept in - 20°C for 4 weeks  | 217 |
| 3.2(o) | Particle size values of various blank liposomes kept in - 20°C for 8 weeks  | 217 |
| 3.2(p) | Particle size values of various blank liposomes kept in - 20°C for 12 weeks   | 217 |
| 3.2(q) | Particle size values of various blank liposomes kept in - 20°C for 24 weeks   | 218 |
| 3.3(a) | Particle size and polydispersity index values of griseofulvin-loaded liposome duo   | 219 |
| 3.3(b) | Particle size and polydispersity index values of griseofulvin-loaded liposome C   | 220 |
| 3.3(c) | Particle size and polydispersity index values of griseofulvin-loaded liposome S   | 221 |
| 3.4(a) | Particle size values of griseofulvin-loaded liposome duo (2mg/g pro-liposomes) prepared using various mixing duration at 25°C | 222 |



|        |  |     |
|--------|--|-----|
| 3.4(b) | Particle size values of griseofulvin-loaded liposome duo (2mg/g pro-liposomes) prepared using various mixing duration at 40°C        | 222 |
| 3.4(c) | Particle size values of griseofulvin-loaded liposome duo (2mg/g pro-liposomes) prepared using various mixing duration at 60°C        | 223 |
| 3.5(a) | Particle size values of griseofulvin-loaded liposome C (2mg/g pro-liposomes) prepared using various mixing duration at 25°C          | 224 |
| 3.5(b) | Particle size values of griseofulvin-loaded liposome C (2mg/g pro-liposomes) prepared using various mixing duration at 40°C          | 224 |
| 3.5(c) | Particle size values of griseofulvin-loaded liposome C (2mg/g pro-liposomes) prepared using various mixing duration at 60°C          | 225 |
| 3.6(a) | Particle size values of griseofulvin-loaded liposome S (2mg/g pro-liposomes) prepared using various mixing duration at 25°C          | 226 |
| 3.6(b) | Particle size values of griseofulvin-loaded liposome S (2mg/g pro-liposomes) prepared using various mixing duration at 40°C          | 226 |
| 3.6(c) | Particle size values of griseofulvin-loaded liposome S (2mg/g pro-liposomes) prepared using various mixing duration at 60°C          | 227 |
| 3.7(a) | Polydispersity index values of griseofulvin-loaded liposome duo (2mg/g pro-liposomes) prepared using various mixing duration at 25°C | 228 |
| 3.7(b) | Polydispersity index values of griseofulvin-loaded liposome duo (2mg/g pro-liposomes) prepared using various mixing duration at 40°C | 228 |

|         |  |     |
|---------|--|-----|
| 3.7(c)  | Polydispersity index values of griseofulvin-loaded liposome duo (2mg/g pro-liposomes) prepared using various mixing duration at 60°C | 229 |
| 3.8(a)  | Polydispersity index values of griseofulvin-loaded liposome C (2mg/g pro-liposomes) prepared using various mixing duration at 25°C   | 230 |
| 3.8(b)  | Polydispersity index values of griseofulvin-loaded liposome C (2mg/g pro-liposomes) prepared using various mixing duration at 40°C   | 230 |
| 3.8(c)  | Polydispersity index values of griseofulvin-loaded liposome C (2mg/g pro-liposomes) prepared using various mixing duration at 60°C   | 231 |
| 3.9(a)  | Polydispersity index values of griseofulvin-loaded liposome S (2mg/g pro-liposomes) prepared using various mixing duration at 25°C   | 232 |
| 3.9(b)  | Polydispersity index values of griseofulvin-loaded liposome S (2mg/g pro-liposomes) prepared using various mixing duration at 40°C   | 232 |
| 3.9(c)  | Polydispersity index values of griseofulvin-loaded liposome S (2mg/g pro-liposomes) prepared using various mixing duration at 60°C   | 233 |
| 3.10(a) | Particle size values of blank liposome duo prepared using various solvents   | 234 |
| 3.10(b) | Particle size values of blank liposome C prepared using various solvents   | 234 |
| 3.10(c) | Particle size values of blank liposome S prepared using various solvents   | 234 |
| 3.11(a) | Polydispersity index values of blank liposome duo prepared using various solvents  | 235 |

|         |  |     |
|---------|--|-----|
| 3.11(b) | Polydispersity index values of blank liposome C prepared using various solvents                                      | 235 |
| 3.11(c) | Polydispersity index values of blank liposome S prepared using various solvents                                      | 235 |
| 3.12(a) | Particle size values of griseofulvin-loaded liposome duo (2mg/g pro-liposome) prepared using various solvents        | 236 |
| 3.12(b) | Particle size values of griseofulvin-loaded liposome C (2mg/g pro-liposome) prepared using various solvents          | 236 |
| 3.12(c) | Particle size values of griseofulvin-loaded liposome S (2mg/g pro-liposome) prepared using various solvents          | 236 |
| 3.13(a) | Polydispersity index values of griseofulvin-loaded liposome duo (2mg/g pro-liposome) prepared using various solvents | 237 |
| 3.13(b) | Polydispersity index values of griseofulvin-loaded liposome C (2mg/g pro-liposome) prepared using various solvents   | 237 |
| 3.13(c) | Polydispersity index values of griseofulvin-loaded liposome S (2mg/g pro-liposome) prepared using various solvents   | 237 |
| 3.14(a) | Particle size values of griseofulvin loaded liposome duo prepared using various amount of griseofulvin               | 238 |
| 3.14(b) | Polydispersity index values of griseofulvin loaded liposome duo prepared using various amount of griseofulvin        | 238 |
| 3.15    | Zeta potential values of various blank liposomes   | 239 |
| 3.16    | Zeta potential values of various griseofulvin-loaded liposomes (2mg/g pro-liposomes)                                 | 240 |

|         |   |     |
|---------|---|-----|
| 3.17(a) | Zeta potential values of griseofulvin-loaded liposome duo prepared using various mixing duration at 25°C                          | 241 |
| 3.17(b) | Zeta potential values of griseofulvin-loaded liposome duo prepared using various mixing duration at 40°C                          | 241 |
| 3.17(c) | Zeta potential values of griseofulvin-loaded liposome duo prepared using various mixing duration at 60°C                          | 241 |
| 3.18(a) | Zeta potential values of griseofulvin-loaded liposome C prepared using various mixing duration at 25°C                            | 242 |
| 3.18(b) | Zeta potential values of griseofulvin-loaded liposome C prepared using various mixing duration at 40°C                            | 242 |
| 3.18(c) | Zeta potential values of griseofulvin-loaded liposome C prepared using various mixing duration at 60°C                            | 242 |
| 3.19(a) | Zeta potential values of griseofulvin-loaded liposome S prepared using various mixing duration at 25°C                            | 243 |
| 3.19(b) | Zeta potential values of griseofulvin-loaded liposome S prepared using various mixing duration at 40°C                            | 243 |
| 3.19(c) | Zeta potential values of griseofulvin-loaded liposome S prepared using various mixing duration at 60°C                            | 243 |
| 3.20(a) | Zeta potential values of various blank liposomes prepared using acetone as solubilization aid                                     | 244 |
| 3.20(b) | Zeta potential values of various blank liposomes prepared using acetonitrile as solubilization aid                                | 244 |
| 3.20(c) | Zeta potential values of various blank liposomes prepared using chloroform as solubilization aid                                  | 244 |
| 3.21(a) | Zeta potential values of various griseofulvin-loaded liposomes (2mg/g pro-liposomes) prepared using acetone as solubilization aid | 245 |

|         |  |     |
|---------|--|-----|
| 3.21(b) | Zeta potential values of various griseofulvin-loaded liposomes (2mg/g pro-liposomes) prepared using acetonitrile as solubilization aid | 245 |
| 3.21(c) | Zeta potential values of various griseofulvin-loaded liposomes (2mg/g pro-liposomes) prepared using chloroform as solubilization aid   | 245 |
| 3.22    | Zeta potential values of griseofulvin-loaded liposome duo prepared using various amount of griseofulvin                                | 246 |
| 3.23    | Encapsulation efficiency of various griseofulvin-loaded liposomes (2mg/g pro-liposomes)  | 247 |
| 3.24(a) | Encapsulation efficiency of griseofulvin-loaded liposome duo prepared using various mixing duration at 25°C                            | 248 |
| 3.24(b) | Encapsulation efficiency of griseofulvin-loaded liposome duo prepared using various mixing duration at 40°C                            | 248 |
| 3.24(c) | Encapsulation efficiency of griseofulvin-loaded liposome duo prepared using various mixing duration at 60°C                            | 248 |
| 3.25(a) | Encapsulation efficiency of griseofulvin-loaded liposome C prepared using various mixing duration at 25°C                              | 249 |
| 3.25(b) | Encapsulation efficiency of griseofulvin-loaded liposome C prepared using various mixing duration at 40°C                              | 249 |
| 3.25(c) | Encapsulation efficiency of griseofulvin-loaded liposome C prepared using various mixing duration at 60°C                              | 249 |
| 3.26(a) | Encapsulation efficiency of griseofulvin-loaded liposome S prepared using various mixing duration at 25°C                              | 250 |
| 3.26(b) | Encapsulation efficiency of griseofulvin-loaded liposome S prepared using various mixing duration at 40°C                              | 250 |

|         |   |     |
|---------|---|-----|
| 3.26(c) | Encapsulation efficiency of griseofulvin-loaded liposome S prepared using various mixing duration at 60°C   | 250 |
| 3.27    | Encapsulation efficiency of various griseofulvin-loaded liposomes (2mg/g pro-liposomes) prepared using various solvents as solubilization aid                 | 251 |
| 3.28    | Encapsulation efficiency of griseofulvin-loaded liposome duo prepared using various amount of griseofulvin  | 252 |
| 4.1     | Animal ethics approval for comparative bioavailability of griseofulvin in aqueous suspension and liposomal formulations of various encapsulation efficiencies | 253 |
| 4.2(a)  | Particle size and polydispersity index values of liposomal formulation 1  | 254 |
| 4.2(b)  | Particle size and polydispersity index values of liposomal formulation 2  | 255 |
| 4.3(a)  | Encapsulation efficiency of griseofulvin in liposomal formulation 1   | 256 |
| 4.3(b)  | Encapsulation efficiency of griseofulvin in liposomal formulation 2   | 256 |
| 4.4(a)  | Plasma griseofulvin concentration of individual rats after oral administration of griseofulvin aqueous suspension   | 257 |
| 4.4(b)  | Plasma griseofulvin concentration of individual rats after oral administration of griseofulvin liposomal formulation1   | 258 |
| 4.4(c)  | Plasma griseofulvin concentration of individual rats after oral administration of griseofulvin liposomal formulation 2  | 259 |
| 5.1     | Animal ethics approval for lymphatic transport study of griseofulvin in aqueous suspension and liposomal formulation  | 260 |

|        |  |     |
|--------|--|-----|
| 5.2(a) | Ratio of griseofulvin concentration in lymph/plasma for individual rats after oral administration of griseofulvin aqueous suspension | 261 |
| 5.2(b) | Ratio of griseofulvin concentration in lymph/plasma for individual rats after oral administration of griseofulvin-loaded liposomes   | 261 |
| 6.1    | Animal ethics approval for comparative bioavailability of griseofulvin in liposomal formulations of various sizes                    | 262 |
| 6.2(a) | Particle size and polydispersity index values of liposomal preparation A   | 263 |
| 6.2(b) | Particle size and polydispersity index values of liposomal preparation B   | 264 |
| 6.2(c) | Particle size and polydispersity index values of liposomal preparation C   | 265 |
| 6.3(a) | Encapsulation efficiency of liposomal preparation A  | 266 |
| 6.3(b) | Encapsulation efficiency of liposomal preparation B  | 266 |
| 6.3(c) | Encapsulation efficiency of liposomal preparation C  | 267 |
| 6.4(a) | Plasma griseofulvin concentration of individual rats after oral administration of liposomal preparation A                            | 268 |
| 6.4(b) | Plasma griseofulvin concentration of individual rats after oral administration of liposomal preparation B                            | 269 |
| 6.4(c) | Plasma griseofulvin concentration of individual rats after oral administration of liposomal preparation C                            | 270 |

# SATU KAJIAN LIPOSOM UNTUK PENGHANTARAN SECARA ORAL SATU DRUG MODEL BERBIOKEPEROLEHAN RENDAH: GRISEOFULVIN

## ABSTRAK

Potensi formulasi liposom sebagai sistem penghantaran drug untuk pengambilan oral drug-drug berbiokeperolehan rendah telah dikaji menggunakan griseofulvin sebagai drug model. Satu teknik ekstrusi menggunakan alat yang dipasang sendiri telah dinilai untuk menano-saizkan liposom. Saiz partikel dan taburan saiz liposom yang dihasilkan dipengaruhi oleh pelbagai parameter pemprosesan. Namun demikian, kaedah ekstrusi adalah ringkas, mudah dihasilkan semula dan lebih berkesan berbanding dengan kaedah pengurangan saiz lain yang dinilai. Kajian *in vitro* menunjukkan bahawa liposom yang disediakan daripada pelbagai pro-liposom, iaitu Pro-lipo duo<sup>®</sup>, Pro-lipo C<sup>®</sup> dan Pro-lipo S<sup>®</sup> semuanya mempunyai saiz berjulat nanometer dengan taburan saiz kecil. Liposom yang disediakan daripada Pro-lipo duo<sup>®</sup> mempunyai saiz yang paling kecil dan adalah paling stabil berbanding dengan pro-liposom yang lain. Kecekapan pemerangkapan griseofulvin dalam liposom dapat ditingkatkan dengan meningkatkan tempoh penyebatian dan suhu ataupun menggunakan pelarut-pelarut organik sebagai alat bantu pemelarutan. Pemerangkapan tertinggi griseofulvin telah dicapai dengan Pro-lipo duo<sup>®</sup> menggunakan kloroform sebagai alat bantu pemelarutan dan oleh itu, ia telah dipilih untuk penilaian *in vivo* yang seterusnya. Kajian perbandingan biokeperolehan *in vivo* mendedahkan bahawa biokeperolehan oral griseofulvin boleh ditingkatkan



sebanyak 2.7-3.2 kali apabila menggunakan liposom, akan tetapi, namun drug yang terperangkap dalam liposom adalah penting untuk meningkatkan penyerapan sistemik. Walau bagaimanapun, peningkatan biokeperolehan griseofulvin dalam formulasi liposom yang diperolehi bukan disebabkan oleh promosi pengangkutan limfatik drug. Tambahan itu, saiz liposom didapati mempengaruhi takat biokeperolehan tetapi tidak menjejaskan tempoh penyerapan griseofulvin. Namun demikian, penyerapan atau biokeperolehan liposom didapati menjadi sama cekap untuk liposom-liposom bersaiz di bawah 400nm, di mana, pengurangan saiz liposom yang selanjutnya mempunyai kesan terhadap ataupun tiada impak selanjutnya pada takat biokeperolehan. Berdasarkan penemuan-penemuan kajian ini, boleh disimpulkan bahawa liposom mempunyai potensi untuk menjadi satu sistem penyampaian drug yang berkesan untuk pengambilan oral drug-drug berketerlarutan air rendah, yang tanpa liposom adalah berbiokeperolehan rendah.

# AN INVESTIGATION OF LIPOSOMES FOR ORAL DELIVERY OF A POORLY BIOAVAILABLE MODEL DRUG: GRISEOFULVIN

## ABSTRACT

The potential of liposomal formulation as a drug delivery system for oral administration of poorly bioavailable drugs was studied using griseofulvin as the model drug. An extrusion technique using a self-assembled instrument was evaluated for nanosizing the liposomes. The particle size and size distribution of liposomes produced was affected by various processing parameters. Nevertheless, the extrusion method was simple, reproducible and more effective compared to other size-reduction methods evaluated. *In vitro* studies showed that liposomes prepared from various pro-liposomes, namely Pro-lipo duo<sup>®</sup>, Pro-lipo C<sup>®</sup> and Pro-lipo S<sup>®</sup> were all in nanometer size range with a narrow size distribution. Liposomes prepared from Pro-lipo duo<sup>®</sup> were smallest in size and most stable compared to other pro-liposomes. The encapsulation efficiency of griseofulvin-loaded liposomes could be enhanced by increasing the mixing duration and temperature or using organic solvents as solubilisation aids. The highest encapsulation of griseofulvin was achieved with Pro-lipo duo<sup>®</sup> using chloroform as the solubilisation aid and hence, it was selected for further *in vivo* evaluations. The *in vivo* comparative bioavailability study revealed that the oral bioavailability of griseofulvin could be increased by 2.7 to 3.2 times using liposomes but the amount of drug encapsulated in the liposomes was important for enhancing the systemic absorption. However, the enhanced bioavailability of griseofulvin in liposomal formulations obtained was not due to the promotion of lymphatic drug

transport. In addition, the size of liposomes was found to affect the extent of bioavailability but has no influence on the duration of griseofulvin absorption. Nonetheless, the uptake or bioavailability of liposomes was found to be equally efficient with liposomes below 400nm, whereby, a further size reduction in the liposomes has limited or no further impact on the extent of bioavailability. On the basis of the findings of this study, it was concluded that liposomes have the potential of being an effective drug delivery system for the oral administration of poorly soluble drugs that are otherwise poorly bioavailable orally.

## CHAPTER 1 INTRODUCTION

### 1.1 BIOAVAILABILITY

#### 1.1.1 INTRODUCTION

The concept of bioavailability, at first called physiological availability, was first introduced in 1945 during the studies of relative absorption of vitamins from pharmaceutical products (Oser *et al.*, 1945). Over the years, the multiplicity of terms used to describe bioavailability had caused considerable ambiguity among the researchers. Confusion has arisen over the interchangeability of the terms used, namely, biologic availability (bioavailability), physiologic availability, generic equivalence and therapeutic equivalence (Wagner, 1975b). After much reviews and debates, bioavailability eventually became the mutually accepted term.

#### 1.1.2 DEFINITION

The U.S. Food and Drug Administration (FDA) defines bioavailability as the rate and extent in which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action (Chen *et al.*, 2001). Since measurement of the drug concentration at the site of action is not always feasible, the bioavailability is more commonly defined as the rate and extent of which an active drug is absorbed from a dosage form and becomes available in the systemic circulation.

### 1.1.3 BARRIERS AFFECTING ORAL BIOAVAILABILITY OF POORLY WATER SOLUBLE DRUGS

The oral route has remained the preferred mode of drug administration, mainly due to its convenience and better patient compliance. However, poorly water-soluble drugs suffer low bioavailability when administered orally (Dahan and Hoffman, 2008, Humberstone and Charman, 1997). Various absorption barriers have been known to affect the oral bioavailability of these drugs (Figure 1.1). They can be categorized into pre-enterocyte, enterocyte and post-enterocyte barriers (Dahan and Hoffman, 2007a).

#### 1.1.3(a) PRE-ENTEROCYTE BARRIERS

##### i) SOLUBILITY

Following oral administration, dissolution of the drug molecule in the intestinal milieu is a prerequisite for the absorption process. If the drug is insoluble or poorly water-soluble, it poses a problem of poor dissolution and/or absorption, since the flux of a drug across the intestinal membrane is proportional to its concentration gradient between the apical side and basolateral sides of gastrointestinal (GI) lumen (Panchagnula and Thomas, 2000).

According to the Biopharmaceutics Classification System (BCS) (Amidon *et al.*, 1995), poorly water-soluble compounds (with solubility less than 100µg/mL) are classified as either class II or class IV compounds, depending on their intestinal permeability. For BCS class II drugs that exhibit high permeability characteristics, drug absorption is governed by their dissolution

in the GI fluids. Whereas, BCS class IV drugs, characterized by both low solubility and poor intestinal wall permeability, are generally poor drug candidates for oral administration.

The aid of surfactants provided by biliary secretions is necessary to solubilize the poorly water-soluble drug and to enable its absorption (Dahan and Hoffman, 2008). These biliary secretions help by forming submicron mixed micelles with the drug and hence enable the solubilized drug to reach the absorptive membrane of the enterocyte. Limited in its capacity and considerably variable in different situations, this process is the rate-limiting step in the absorption of the poorly water-soluble drugs and often becomes a significant absorption barrier (Dahan and Hoffman, 2007a).

## ii) LIMITED ABSORPTION SITE

The absorption of the poorly water-soluble drugs usually takes place along the small intestine, where drug solubilization occurs. The residence time of a drug in the upper GI tract has been shown to be relatively short and the transit time along the small intestine is about 3.0-4.5 hours in healthy volunteers (Yu and Amidon, 1999). Although fat can prolong the small intestinal transit time (by 30-60 minutes), it is not thought to be of any significance in drug delivery (Dahan and Hoffman, 2007a). As a result, the absorption of a poorly water-soluble drug may be poor due to limited site of absorption, and if the drug reaches the colon prior to solubilization, its bioavailability is expected to be even lower.




Figure 1.1 Barriers affecting oral bioavailability of poorly water-soluble drugs (adapted from Dahan and Hoffman, 2008)

### iii) UNSTIRRED WATER LAYER

The unstirred layer refers to the stagnant layer of water adjacent to the absorptive membrane of the enterocyte (Ashford, 2002). It can be visualized as a series of water lamellas, each progressively more stirred from the gut wall toward the lumen bulk (Dahan and Hoffman, 2008). For BCS class II drugs, the rate of permeation through the brush border is fast due to large surface area and thus the diffusion across the unstirred water layer (UWL) becomes the rate-limiting step in the permeation process. A study by Read *et al.* (1977) found that the thickness of the UWL in human jejunum is over 500 $\mu$ m. Due to its thickness and hydrophilicity, the UWL may represent a major permeability barrier to the absorption of poorly water-soluble drugs. In addition, the effective surface area of the UWL also plays a role in limiting drug absorption. The ratio of the surface area of the UWL to that of the underlying brush border membrane is at least 1:500 (Westergaard and Dietschy, 1974). This low ratio value suggests that the effective surface area of the UWL available for the absorption of poorly water-soluble drugs is relatively small, and hence, their bioavailability are impaired.

### 1.1.3(b) ENTEROCYTE BARRIERS

Upon entering the enterocyte, a drug molecule faces another set of biochemical barriers that affect the magnitude of its absorption. The cytochrome P450 3A4 (CYP3A4) enzymes, located in the endoplasmic reticulum of the enterocyte, are responsible for most drug metabolism in the intestinal wall. A study by Wachter *et al.* (1998) found that this isoenzyme accounted for more than 70% of all small intestinal CYP450s. While some



transporters located in the apical wall of the enterocyte facilitate absorption, there are others that serve as efflux transporters. Efflux transporters play a major role in the disposition of many drugs, and thus, are regarded as the multiple drug resistance (MDR) transporters. The apical P-glycoprotein (P-gp) efflux pump is the most extensively studied MDR transporter. It reduces the fraction of drug absorbed by transporting the drug from the enterocyte back to the intestinal lumen (Gottesman *et al.*, 1996).

Synergism exists between the activity of the metabolic CYP3A4 enzymes and the P-gp system. A drug molecule that escapes the intra-enterocyte metabolism may either reach the blood circulation or be effluxed back into the GI lumen, and then may be reabsorbed (Benet and Cummins, 2001). Many studies have shown that these two pre-hepatic systems contributed to the limited oral bioavailability of many poorly water-soluble drugs (Lennernäs, 2003, Fitzsimmons and Collins, 1997, Thummel *et al.*, 1996, Kolars *et al.*, 1991).

### 1.1.3(c) POST-ENTEROCYTE BARRIERS

A drug molecule that manages to escape the intra-enterocyte metabolism and the MDR efflux systems will diffuse across the cell and be secreted from the basolateral membrane of the enterocyte into the lamina propria. Following that, the drug is usually absorbed into the portal blood unless it is being incorporated into a chylomicron. However, before reaching the systemic blood circulation, the drug molecules will have to pass through the liver, and hence are exposed to the metabolic enzymes. This first-pass

hepatic metabolism has been shown to be a major barrier to the absorption of poorly water-soluble drugs, which are the most likely molecules to undergo oxidative metabolism.

#### 1.1.4 APPROACHES TO ENHANCE THE ORAL BIOAVAILABILITY OF POORLY WATER-SOLUBLE DRUGS

Low oral bioavailability of poorly water-soluble drugs poses a great challenge during drug development (Lipinski *et al.*, 1997). Various approaches have been developed to improve the bioavailability by increasing the drug dissolution rate and solubility. A summary of the strategies and approaches is detailed in the following sections.

##### 1.1.4(a) PRODRUGS

The term prodrug may be defined as a chemical derivative of a drug that is bioconvertible into the active parent drug or an active metabolite responsible for the therapeutic effect (Kim and Singh, 2002). Prodrugs are formed by attachment of the active drug through a metabolically labile linkage to another molecule, the “promoiety”, to impart some desirable properties to the drug. Chloramphenicol for example, was chemically modified to produce a prodrug, chloramphenicol sodium succinate with enhanced solubility. As a result of this modification, its aqueous solubility was improved significantly from 2.5 mg/ml to 100 mg/ml (Maurin *et al.*, 2002). Besides that, prodrugs can be designed to improve the bioavailability via other means. L-Dopa for instance improved the bioavailability of dopamine by overcoming the blood-brain

barrier; whereas, propranolol hemisuccinate blocked the formation of glucuronide which resulted in a reduction of the first-pass metabolism to increase the bioavailability of propranolol (Anderson *et al.*, 1988).

#### 1.1.4(b) COMPLEXATION

Cyclodextrins have been extensively utilized as complexing agents to improve the bioavailability of numerous poorly water-soluble drugs (Figeiras *et al.*, 2007, Larsen *et al.*, 2005, Green and Guillory, 1989). The cyclic oligosaccharides obtained from the enzymatic degradation of starch have a unique structure of an apolar cavity and a hydrophilic external part, which renders them to mask the physicochemical properties of the included drug molecule. The mechanism of bioavailability enhancement by cyclodextrins complexation has been attributed to the improvement of solubility, dissolution rate and chemical stability (Loftsson and Brewster, 1996). In addition to the inclusion of complexes formed by cyclodextrins, other types of molecular complexes, such as caffeine, sodium salicylate, sodium benzoate and nicotinamide have also been reported.

#### 1.1.4(c) COSOLVENT APPROACH

A cosolvent is a water-miscible organic solvent that is used to increase aqueous solubility of a poorly water-soluble compound or to increase the chemical stability of a drug. Due to their low toxicity, ethanol, glycerol and polyethylene glycols (PEGs), are commonly selected for formulating poorly water-soluble drugs (Strickley, 2004). In a recent study, the cosolvent technique used for the preparation of carbamazepine nanosuspensions not

only increased the aqueous solubility of carbamazepine but also improved the stability of the formulations (Douroumis and Fahr, 2007).

#### 1.1.4(d) PARTICLE SIZE REDUCTION

The dissolution rate of a drug can be proportionally increased by increasing its surface area as a consequence of comminution. The bioavailability of the antifungal, griseofulvin, was enhanced significantly by micronization and hence the effective dose was reduced by 50% (Atkinson *et al.*, 1962). Absorption of naproxen was faster and the plasma levels were higher when the drug was administered orally (to rats) as nanoparticles, compared to that administered as conventional drug particles (Liversedge and Conzentino, 1995). Besides that, several studies with a number of poorly water-soluble drugs, such as cilostazol, danazol and cyclosporine, have also demonstrated that particle size reduction can lead to an increased rate of dissolution and improved oral bioavailability (Jinno *et al.*, 2006, Liversedge and Cundy, 1995, Tarr and Yalkowsky, 1989). Therefore, nano-sized particles are now being considered to boost absorption of poorly water-soluble drugs.

#### 1.1.4(e) PHARMACEUTICAL SALTS

Salt formation is a simple means to alter the biopharmaceutical properties of a drug substance, particularly useful to enhance drug solubility. Salt formation increases drug solubility by keeping the pH at which the drug is ionized (Perumal and Podaralla, 2008). Numerous studies have shown that the solubility of poorly water-soluble drugs such as piroxicam (Gwak *et al.*,

2005), meloxicam (Han and Choi, 2007) and diclofenac (O'Connor and Corrigan, 2001) could be enhanced via salt formation.

#### 1.1.4(f) LIPID-BASED FORMULATIONS

The use of lipid as a potential formulation strategy for improving the oral bioavailability of poorly water-soluble drugs has generated much academic and commercial interest. Lipid-based formulations of poorly water-soluble drugs offer a large versatility for oral administration as they can be formulated as solutions, gels, suspensions, emulsions, self-emulsifying systems, liposomes and solid dispersions (Gershanika and Benita, 2000, Pouton, 2000). The role of liposomes in oral delivery of poorly water-soluble drugs will be reviewed in section 1.3.

Incorporation of the poorly water-soluble drugs into inert lipid vehicles could enhance the absorption and oral bioavailability via a combination of various mechanisms that are described in the following section. All these mechanisms could help to improve the oral bioavailability of drugs.

## 1.2 MECHANISMS OF LIPID-BASED FORMULATIONS IN ENHANCING THE ORAL BIOAVAILABILITY OF POORLY WATER-SOLUBLE DRUGS

The ability of lipid vehicles to enhance the bioavailability of poorly water-soluble drugs has been well known for many years. The presentation of the poorly water-soluble drug as a solution in oil, avoiding the complexities associated with solid state, is a major factor for this bioavailability enhancement (Dahan and Hoffman, 2008). The other mechanisms by which lipid based delivery systems enhance the bioavailability of poorly water-soluble drugs include:

### i) Enhanced dissolution / solubilization

The presence of lipids in the GI tract stimulates an increase in the secretions of bile salts (BS) and endogenous biliary lipids such as phospholipids (PL) and cholesterol (Fleisher *et al.*, 1999). These biliary products, along with the gastric shear movement, form crude emulsion which promotes the solubilization of the coadministered poorly water-soluble drug (Tso, 1985). In addition, the exogenous lipidic component of the delivery system is subjected to enzymatic digestion. Esters are rapidly hydrolyzed in the presence of pancreatic lipase and the lipolytic products, upon interaction with BS or PL, form different micellar species that prevent precipitation of the coadministered poorly water-soluble drug (Dahan and Hoffman, 2008).

ii) Prolongation of gastric residence time

Lipids in the GI tract delay gastric emptying and thereby increasing the gastric transit time. As a result, the residence time of the coadministered poorly water-soluble drug in the small intestine is prolonged. This enables longer exposure of the drug at the absorptive site, and thereby improves its absorption (Hunt and Knox, 1968).

iii) Stimulation of lymphatic transport

Bioavailability of poorly water-soluble drugs may be enhanced also by the stimulation of the intestinal lymphatic transport pathway. Further discussions are in section 1.2.2.

iv) Influence of intestinal permeability

Various combinations of lipids, lipid digestion products and surfactants have been shown to possess permeability enhancing properties (Aungst, 2000). In most instances, however, passive intestinal permeability is not thought to be a major barrier to the bioavailability of lipophilic drugs (Porter and Charman, 2001a).

v) Reduced metabolism and efflux activity

Certain lipids and surfactants have been shown to reduce the activity of the efflux transporters in the GI wall, and hence, increase the fraction of drug absorbed (Dintaman and Silverman, 1999). Because synergism exists between the activity of P-gp and CYP3A4, these lipids and surfactants may also reduce the intra-enterocyte metabolism (Dahan and Hoffman, 2008).

### 1.2.1 DIGESTION AND ABSORPTION OF LIPIDS FROM GASTROINTESTINAL TRACT

As mentioned in section 1.2, lipid-based formulations can reduce the inherent limitation of slow and incomplete dissolution of poorly water-soluble drugs, and facilitate the formation of solubilized phases from which absorption may occur. The attainment of a solubilized phase will not necessarily arise directly from the administered lipid, but most likely from the intraluminal processing to which lipids are subjected prior to absorption (Humberstone and Charman, 1997, MacGregor *et al.*, 1997). Therefore, an understanding of lipid digestion and the manner by which it contributes to drug solubilization is vital to the design of lipid-based formulations.

The lipid digestion and absorption process, and its direct association with lymphatic transport of lipophilic drugs, has been extensively reviewed (Humberstone and Charman, 1997, Porter and Charman, 1997, Tso, 1985, Carey *et al.*, 1983). Firstly, lingual and gastric lipases initiate hydrolysis of a limited amount of triglyceride (TG), forming the corresponding diglyceride (DG) and fatty acid (FA) within the stomach. These amphiphilic lipid digestion products, in combination with the shear mixing produced by antral contraction, retropulsion and gastric emptying, facilitate the formation of a crude emulsion which empties into the duodenum. In duodenum, the emulsion induces the secretion of bile salts, biliary lipids and pancreatic fluids into the duodenum. Biliary lipids adsorb onto the surface of the emulsified lipids, improving the colloidal stability and further reducing their particle size (Carey *et al.*, 1983). Subsequently, the hydrolysis of the emulsified lipids



takes place under the action of pancreatic lipase. This interfacial enzyme which requires co-lipase and bile salts to be active, acts at the surface of the emulsified TG droplets to quantitatively produce the corresponding 2-monoglyceride (MG) and two molecules of FA.

Polar digestion products such as short-chain and medium-chain FAs diffuse across the mucosa lining of the enterocyte and enter into the portal circulation (Kiyasu *et al.*, 1952). On the other hand, the non-polar digestion units such as the long-chain FAs (more than 12 carbons) and MG are emulsified by bile salts to form micelles. Micelles are not absorbed intact. The lipid monomers dissociate from the micelles and are subsequently absorbed from a monomolecular inter-micellar phase (Westergaard and Dietschy, 1976). In addition to passive uptake, long-chain FAs and their substrates may utilize an enterocyte-based carrier system, called the microvillus membrane fatty acid binding protein (MVM-FABP) (Stremmel, 1988, Stremmel *et al.*, 1985). Once inside the cell, the long-chain FAs are re-esterified to form triglycerides, which are incorporated into lipoproteins to form chylomicrons (Davidson, 1994). The chylomicrons cannot permeate the blood capillaries due to its large particle size (200-800 $\mu$ m) (Dahan and Hoffman, 2007a). Thus, they are absorbed into a porous mesenteric lymph vessel called lacteal and travel with the lymph until drainage into the systemic blood circulation.

### 1.2.2 INTESTINAL LYMPHATIC DRUG TRANSPORT

The majority of orally administered drugs gain access to the systemic circulation by direct absorption into the portal blood (Porter and Charman, 2001a). However, for some poorly water-soluble compounds, transport by way of the intestinal lymphatic system may provide an additional route of access into the systemic circulation (Porter and Charman, 2001a). Bypassing the liver, an alternative absorption pathway from the GI tract, provides an advantage over the portal blood route for avoidance of potential hepatic first-pass metabolism, as discussed in section 1.1.3(c). It has been shown to enhance the bioavailability of a number of lipophilic drugs including the fat-soluble vitamins (Dahan and Hoffman, 2007a), halofrantrine (Holm *et al.*, 2003), probucol (Palin and Wilson, 1984) and cyclosporine (Ueda *et al.*, 1983). Lipid-based vehicles and the presence of food often enhance the oral bioavailability particularly of poorly water-soluble drugs. In some cases, the lymphatic system plays a significant role in this enhanced bioavailability. Therefore, it seems likely that the physiological processes of lipid digestion and absorption are relevant to this enhanced drug delivery.

Lipid vehicles may enhance lymphatic transport of lipophilic compounds by stimulating the production of chylomicrons (O'Driscoll, 2002). Lipophilic drugs enter the lymphatic system in association with the triglyceride core of the chylomicrons. In many cases, for example with the antimalarial drug halofantrine (log P 8.5, TG solubility 50 mg/ml), a strong correlation has been established between the degree of lymphatic drug transport and the TG content of the lymph (Caliph *et al.*, 2000). The importance of the physiological

process of lipid digestion in stimulating drug lymphatic transport has also been highlighted by Liu *et al.* (1995). Following administration of a milk fat globule membrane (MFGM) stabilized soybean emulsion, 19.2% of the dose of vitamin D<sub>3</sub> was transported via the lymph, but the degree of transport dropped to 0.27% in rats with pancreatic duct ligation. On the other hand, when the MFGM emulsion was administered with bile salt and pancreatic lipase, the extent of lymphatic transport was increased again to 20.4%.

Even with lipid-based formulations, various factors were found to influence the extent of lymphatic transport. These include the chemical structure, digestibility and dispersed state of the lipid vehicle. One of the earliest reports of intestinal lymphatic transport by Palin *et al.* (1982) illustrated the importance of the digestibility of the vehicle on the extent of lymphatic transport. Arachis oil was found to significantly increase the lymphatic transport of dichlorodiphenyltrichloroethane (DDT) relative to non digestible liquid paraffin. In addition, long-chain unsaturated FAs were found to be more capable of enhancing lymphatic transport, and this has been attributed to their increased ability to stimulate chylomicron production (Charman *et al.*, 1986a, Palin *et al.*, 1982). Besides that, a study by Porter *et al.* (1996a) supported the hypothesis that formulations of lipids as dispersed systems may promote the lymphatic transport.

## 1.3 LIPOSOMES

### 1.3.1 INTRODUCTION

Liposomes are naturally occurring self-assembled structures that can also be synthesized in the laboratory (Gómez-Hens and Fernández-Romero, 2005). They are composed of one or several lipid bilayers enclosing aqueous compartments and may range in size from tens of nanometers to tens of microns in diameter. Liposomes are usually made of phospholipids, a class of amphiphilic molecules (possessing both hydrophilic and lipophilic properties) (Figure 1.2) which is the main components of biological membranes. In aqueous medium, phospholipids arrange themselves into bilayers, by positioning their hydrophilic groups towards the surrounding aqueous medium, and their lipophilic chains towards the inner side of the bilayer.

The potential of liposomes as drug delivery systems has been widely recognized (Torchilin, 2005, Vemuri and Rhodes, 1995, Woodle and Papahadjopoulos, 1989, Fendler and Romero, 1977, Gregoriadis, 1976). Drugs with widely varying lipophilicities can be encapsulated into liposomes, either in the phospholipid bilayer, in the encapsulated aqueous volume or at the bilayer interface (Sharma and Sharma, 1997) ( Figure 1.3). Hydrophobic drugs are incorporated into the lipid bilayers, while hydrophilic drugs are usually encapsulated in the aqueous compartments (Barenholz, 2003). For drug delivery, liposomes can be formulated as a suspension, an aerosol, or a semisolid preparation such as a gel or cream, or a solid preparation like a dry powder (Lasic, 1998).




Figure 1.2 Structural formula of a phospholipid molecule




Figure 1.3 Distribution of drugs of different lipophilicities in liposomes (adapted from Sharma and Sharma, 1997)

Various routes of administration, namely parenteral, topical and oral, can be used for administration of liposomes (Betageri *et al.*, 1993a). Many studies on liposomes as drug delivery systems employed the parenteral route. In addition to intravenous (i.v.) administration, liposomes have been administered via the intraperitoneal (i.p.), intramuscular (i.m.) and subcutaneous (s.c.) routes (Crommelin and Schreier, 1994, Zonneveld and Crommelin, 1988). Topical administration of liposomes includes application to the skin, eyes, lungs or body cavities. Thus, liposomes may be used for either local or systemic delivery of drugs (Betageri *et al.*, 1993a). Besides that, liposomes have been used successfully as an oral drug delivery system. Examples of drugs that showed improved bioavailability when administered orally in liposomal formulations include heparin (Jiao *et al.*, 2002), insulin (Iwanagaa *et al.*, 1997), cyclosporine (Al-Meshala *et al.*, 1998), erythropoietin (Maitani *et al.*, 2000a) and cefotaxime (Ling *et al.*, 2006).

### 1.3.2 CLASSIFICATION OF LIPOSOMES

On the basis of their size and number of bilayers, liposomes can be classified as (Sharma and Sharma, 1997, Betageri *et al.*, 1993b):

#### (a) multilamellar vesicles (MLVs)

MLVs usually consist of vesicles covering size range of 100 to 1000nm, each vesicle consisting five or more concentric bilayers. Vesicles, which are composed of less than five bilayers, are called oligo-lamellar vesicles.

(b) large unilamellar vesicles (LUVs)

LUVs have diameters larger than 100nm in size and consist of one lipid bilayer. Liposomes with sizes between 50 and 100nm are referred to as intermediate sized unilamellar vesicles.

(c) small unilamellar vesicles (SUVs)

SUVs are the lower sized liposomes. Their sizes depend on the ionic strength of the aqueous media and lipid composition, and are usually in the range 25 to 50nm. They possess only one lipid bilayer.

Besides classification based on the number of bilayers and size, liposomes can also be categorized in terms of their composition and mechanism of intracellular delivery (Sharma and Sharma, 1997). They are:

(a) Conventional liposomes (CLs)

CLs are composed of neutral and/or negatively charged phospholipids and cholesterol. As the contents of CLs are ultimately delivered to the lysosomes, CLs are therefore useful for reticuloendothelial system (RES) targeting.

(b) pH-sensitive liposomes

They consist of phospholipids with either cholesteryl hemisuccinate or oleic acid. At low pH, they fuse with cell membranes and release their contents in cytoplasm.



(c) Cationic liposomes

These usually compose of cationic lipid derivatives and neutral phospholipids. In most cases, they fuse with the cell membranes and are suitable for delivery of negatively charged macromolecules.

(d) Long-circulating liposomes (LCLs)

LCLs are also known as 'Stealth Liposomes'. They consist of neutral phospholipids with high transition temperature ( $T_c$ ) and cholesterol with hydrophilic surface coating. The surface coating sterically hinders a variety of interactions at the bilayer surface, so that the liposomes can escape the rapid uptake by macrophage cells of the RES, and thus circulate in the blood stream for a long time and passively target onto sites of tumors, infection and inflammation, often characterized by the presence of a leaky vasculature.

(e) Immunoliposomes

These are CLs or LCLs with attached antibody or recognition sequence. They participate in cell-specific binding (targeting) and release their contents extracellularly near the target tissue.

### 1.3.3 CHEMICAL CONSTITUENTS

Liposomes can be prepared from a variety of lipids and other amphiphiles such as nonionic surfactants. The vesicles prepared from the latter are referred to as niosomes and are mainly used for topical application. Phospholipids, the most commonly used lipid for liposome preparation, can

be divided into four groups (van Winden *et al.*, 1998, Barenholz and Crommelin, 1994):

(a) Natural phospholipids

The two main sources of natural phospholipids are eggs and soy beans. Natural phospholipids are usually present in a mixture of phospholipids with different chain length and varying degrees of unsaturation (New, 1990). Generally, plant-derived phospholipids have higher level of unsaturation in the fatty acyl chains compared to those of animal-derived. Natural phospholipids which are used for preparation of liposomes include phosphatidylcholine (PC), phosphatidylethanolamine (PE), sphingomyelin and phosphatidylinositol (PI).

(b) Modified natural phospholipids

These are natural phospholipids that are chemically modified to alter certain characteristics of the phospholipids. The acyl chains of natural phospholipids can be modified by partial or complete hydrogenation. Such modification reduces the degree of unsaturation (to different extents) and consequently improves the phospholipids' appearance and resistance to peroxidation (Barenholz and Crommelin, 1994). Another possible modification is conversion of head group of phospholipids with the aid of the enzyme phospholipase D.

(c) Semisynthetic phospholipids

They are obtained by removing the acyl chains of natural phospholipids by chemical replacement with defined synthetic acyl chains (Lichtenberg and Barenholz, 1988).

(d) Fully synthetic phospholipids

These compounds are prepared via complete chemical synthetic pathways. Fully synthetic phospholipids have the advantage of a defined fatty acid composition and can be tailored to specific needs.

Apart from phospholipids, other lipids used in liposome preparation include sterols, especially cholesterol. Cholesterol does not by itself form bilayer structures but can be incorporated into the phospholipid bilayer to provide greater stability (New, 1990). Cholesterol reduces the fluidity of the bilayer above the transition temperature, resulting in a corresponding reduction in the permeability to aqueous solutes. Cholesterol can be incorporated up to a level of 50 mol% (1:1 ratio), at which it displays its maximum stabilizing effect both *in vitro* and *in vivo* (New, 1990).

#### 1.3.4 METHODS OF PREPARATION

Liposomes can be prepared according to three basic modes of preparation namely mechanical dispersion, solvent dispersion and detergent solubilization (Figure 1.4).




Figure 1.4 Classification of methods of liposome preparation (adapted from Jain 2001)